Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. In a double-blind, phase 3 trial, we randomly assigned patients ...

1 The most common variant in gliomas causes an amino acid change at position 132 of the IDH1 protein (IDH1 R132H), which results in a new, oncogenic enzymatic activity: mutant IDH (mIDH ...

More information: Syeda Maheen Batool et al, Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas, Nature Communications (2024). DOI: 10.1038/s41467-024-51332-7 ...

Let’s hear the thoughts of some of the world’s leading glioma experts on the data from the study A Multilingual Overview of the INDIGO Study Data (Presented by Clinical Experts in French ...

“Patients with grade two glioma who had IDH1 mutation treated with Vorasidenib doubled in terms of survival. And it’s a remarkable story. It’s splashed all over the media, and it’s a game ...

Researchers previously found somatic mutations in the gene for isocitrate dehydrogenase 1 (IDH1) in 83% of secondary GBMs (arising from lower-grade gliomas) but in only 7% of primary GBMs (arising ...

Different gliomas may have changes in different genes, such as the BRAF, IDH1, or IDH2 genes. If your child has a glioma, their treatment options and outlook may vary depending on whether the ...

NEO-100-01, according to the news release, is the first intranasal therapy of its kind of be evaluated in the treatment of malignant gliomas, specifically targeting IDH1-mutant grade 3 and 4 ...

The new FDA approval is for Servier’s Voranigo, or vorasidenib, for adult and children ages 12 and older with low-grade glioma with a susceptible IDH1 or IDH2 mutation. As the FDA noted in its ...